



EDGE MEDICAL

2025

Environmental, Social and Governance Report

Shenzhen Edge Medical Co., Ltd.

# Contents

About this Report	01
About Edge Medical	02
Sustainability Management	06

## Strengthening Governance for Sustainable Growth

Corporate Governance	11
Business Ethics	12
Medical Ethics	13
Information Security	13

## Advancing Low-carbon Development, Fulfilling Our Responsibilities

Climate Change	26
Environmental Management	28
Resource Use	29
Emissions	30

## Integrity and Innovation, Quality for the Future

Quality Management	15
Customer Service	17
Technological Innovation	17
Intellectual Property Protection	18
Responsible Marketing	18

## Working with Partners to Build a Better Life

Sustainable Supply Chain	32
Industry Exchange	33
Community Development	35

## Growing Together, Empowering Our People

Employee Rights and Interests	20
Employee Development	22
Employee Safety	23
Care and Communication	24

<b>Outlook for 2026</b>	<b>36</b>
<b>ESG Index</b>	<b>37</b>
<b>Feedback Form</b>	<b>41</b>

# About this Report

This report is the first Environmental, Social and Governance Report of Shenzhen Edge Medical Co., Ltd. (the “ESG Report”). It aims to disclose, in a transparent and open manner, the Company’s management approach and specific practices in relation to ESG issues, as well as the related results achieved in 2025, in response to stakeholders’ concerns and expectations regarding the Company’s sustainable development.

## Reporting Scope

This report primarily discloses the ESG performance and related information of Shenzhen Edge Medical Co., Ltd. and its subsidiaries for the period from January 1, 2025 to December 31, 2025.

## Basis of Preparation

This Report has been prepared primarily in accordance with Appendix C2 Environmental, Social and Governance Reporting Code to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

## Reporting Principles

Materiality	During the preparation of this report, issues closely related to the Company’s operations and those of concern to major stakeholders were identified, and the management approaches, measures and relevant performance of such material ESG issues are disclosed in the report.
Quantitative	Environmental, social and governance KPIs have been established and quantitatively disclosed with reference to Appendix 2: Reporting Guidance on Environmental KPIs and Appendix 3: Reporting Guidance on Social KPIs in How to Prepare an ESG Report issued by the Stock Exchange, so as to monitor and assess the Company’s progress in fulfilling its environmental and social responsibilities.
Consistency	Consistent statistical methodologies are adopted in this report to enable effective and meaningful comparisons of data over time.
Balance	The ESG Report follows the principle of balance and discloses both positive and negative information of the Company in an unbiased manner, so as to present an objective picture of the Company’s ESG management and practices.

This ESG Report complies with the “comply or explain” requirements under the ESG Reporting Code, and explanations are provided for certain indicators that are not applicable.

## Information Statement

The data and case studies contained in this report are derived from the internal statistical data and relevant documents of Shenzhen Edge Medical Co., Ltd. The Company is responsible for the truthfulness, accuracy and completeness of the contents of this report. This report is published in Traditional Chinese and English. In the event of any discrepancy between the two language versions, the Traditional Chinese version shall prevail. Unless otherwise specified, all monetary amounts referred to in this report are denominated in Renminbi.

## References to the Company

For ease of expression and reading, “Shenzhen Edge Medical Co., Ltd.” may also be referred to in this report as “Edge Medical,” the “Company,” or “we.”

## Approval of the Report

This report was considered and approved by the Board on March 27, 2026 and is hereby published.

## Availability of the Report

This report is available in both Traditional Chinese and English. The electronic version may be accessed on the HKEXnews website of The Stock Exchange of Hong Kong Limited (<https://www.hkexnews.hk>) and the official website of Edge Medical (<https://www.edgemed.cn>).

# About Edge Medical

## Company Profile

Founded in Shenzhen in May 2017, Edge Medical is a surgical robotics company focused on independent research and development and is listed on the Main Board of The Stock Exchange of Hong Kong Limited.

The Company is committed to independent innovation and has independently mastered core technologies across the full surgical robotics value chain, forming a comprehensive proprietary intellectual property system. Based on seven self-developed platform technologies, it has established a rich and comprehensive product portfolio covering its Edge Multi-Port Endoscopic Surgical Robot, Edge Single-Port Endoscopic Surgical Robot and Edge Bronchoscope Robot.

The Company has long focused on the field of high-end surgical robots and has continuously advanced indigenous innovation and clinical application of high-end medical equipment. It was awarded the Second Prize of the 2023 National Science and Technology Progress Award and successfully carried out multiple transcontinental robotic telesurgeries, among which the 12,035-kilometre telesurgery was certified by Guinness World Records.

The Company continues to advance its international expansion and commercial scale-up, and has launched a “three-in-one” surgical solution integrating multi-port, single-port and telesurgery systems to promote cross-regional and cross-border sharing of quality medical resources and to drive the development and wider adoption of surgical technologies.

## Corporate Culture

### Mission



To advance surgical technology, empower surgeons and benefit patients

### Vision



To equip every surgical room with surgical robot

### Philosophy



To persistently pursuit of perfection in technologies to create the finest products



## Development History

### ◆ Begin

#### 2017

- Jingfeng Medical, being our predecessor, was established in the PRC
- We established our manufacturing facilities in Shenzhen with an aggregate area of approximately 6,000 sq.m

### ◆ Leap

#### 2021

- SP1000 became eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices
- We completed registrational clinical trial in urologic surgery with MP1000
- We initiated clinical trial in gynecologic surgery with both MP1000 and SP1000
- We cooperated with Class III Grade A hospitals, and established nationwide network of training centers

2017-2021

### ◆ Breakthrough

#### 2022

- MP1000 became eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices
- We initiated clinical trial in general surgery and thoracic surgery with MP1000
- We completed the registrational clinical trials of both MP1000 and SP1000 in gynecologic surgery
- We obtained the Class III medical device registration certificate of MP1000, the first model of our Edge Multi-Port Endoscopic Surgical Robot
- MP1000 was approved for urologic surgery by the NMPA
- We started to commercialize Edge Multi-Port Endoscopic Surgical Robot in China

#### 2023

- The NMPA approved our registration modification to expand the clinical applications of MP1000 in urologic surgery, gynecologic surgery, general and thoracic surgery of adults
- MP1000 became the first domestically-developed endoscopic surgical robot approved by the NMPA for applications in multiple surgical specialties, according to Frost & Sullivan
- For Edge Multi-Port Endoscopic Surgical Robot, the NMPA further approved our registration modification to include (i) the fluorescence imaging function that enables visible light and near-infrared (NIR) fluorescence imaging at the surgical site, with NIR imaging requiring use in combination with NMPA approved indocyanine green (ICG) at the same location, and (ii) the dual console control
- We obtained the Class III medical device registration certificate of SP1000, the first model of our Edge Single-Port Endoscopic Surgical Robot. SP1000 was approved by the NMPA for application in gynecologic surgery
- We started to commercialize Edge single-Port Endoscopic Surgical Robot in China

2022-2023

### ◆ Lead

#### 2024

- For Edge Multi-Port Endoscopic Surgical Robot, the NMPA approved our registration modification to include our MP2000 series, comprising three models with improved ergonomics, improved computer power, advanced algorithms, full-phase fluorescence imaging and full-stack technological design
- For Edge Single-Port Endoscopic Surgical Robot, the NMPA further approved our registration modification to expand the clinical applications of SP1000 in urologic surgery and general surgery
- SP1000 became China's first (but currently not the only) singleport endoscopic surgical robot approved by the NMPA covering three or more major surgical specialties

#### 2025

- We obtained the CE Marking of MP1000 in the EU
- We obtained the Class III medical device registration certificate of CP1000, the first model of our Edge Bronchoscope Robot and China's first two-arm bronchoscope robot. It was approved by the NMPA for application in preoperative planning of natural orifice bronchoscopy procedures and treatments
- We obtained the CE Marking of SP1000 in the EU

#### 2026

- Successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited, entering the international capital market
- The world's first and, to date, only integrated surgical robotic platform featuring multi-port, single-port and telesurgery capabilities, independently developed by Edge Medical®, officially obtained NMPA approval
- The Edge® Single-Port Endoscopic Surgical Robot received approval covering all four core surgical specialties

2024-Present

## Corporate Honors

Second Prize of the 2023 National Science and Technology Progress Award (Innovation and Promotional Application of Precision Minimally Invasive Intelligent Diagnosis and Treatment Technology for Bladder Cancer)

Central Committee of the Communist Party of China and the State Council of the People's Republic of China

Guangdong Provincial Surgical Robot Engineering Technology Research Center

Department of Science and Technology of Guangdong Province

High-tech Enterprise

Shenzhen Municipal Bureau of Industry and Information Technology, Shenzhen Municipal Bureau of Finance, and Shenzhen Municipal Tax Service of the State Taxation Administration

Unicorn Enterprise

Shenzhen Gazelle and Unicorn Enterprise Evaluation Committee

Specialized, Sophisticated, Distinctive and Innovative "Little Giant" Enterprise

Ministry of Industry and Information Technology

Partner of the Artificial Intelligence-assisted Treatment (Robotics) Technology Training Base of the Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangdong Provincial Training Base for Artificial Intelligence-assisted Treatment Technology

First Prize of the 2021 Guangdong Provincial Science and Technology Progress Award

People's Government of Guangdong Province

2021 Shenzhen High-growth Enterprise TOP100 (No. 5)

Shenzhen Enterprise Evaluation Association

Edge Medical's surgical robot system set the Guinness World Record for the world's longest-distance remote surgery at 12,035 km



## Major Events in 2025

### January

The Edge Bronchoscope Robot CP1000 independently developed by Edge Medical officially obtained marketing approval from the NMPA (Registration Certificate No.: 20253010298).

### March

The Edge Multi-Port Endoscopic Surgical Robot independently developed by Edge Medical officially obtained the CE Marking (MDR) in the EU, applicable to endoscopic surgical fields including urology, gynecology, general surgery and thoracic surgery.

### August

The Edge Multi-Port Endoscopic Surgical Robot officially obtained registration approval from the Brazilian Health Regulatory Agency (ANVISA), applicable to endoscopic surgical fields including urology, gynecology, general surgery and thoracic surgery.

### October

The Edge Single-Port Endoscopic Surgical Robot SP1000 and the single-/multi-port surgical robot super system independently developed by Edge Medical officially obtained the CE Marking (MDR) in the EU, applicable to endoscopic surgical fields including urology, gynecology, general surgery and thoracic surgery.

### November


The Edge Cloud Telesurgery System independently developed by Edge Medical officially obtained marketing approval from the NMPA.

The Edge Multi-Port Endoscopic Surgical Robot independently developed by Edge Medical officially obtained marketing authorization from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) of Mexico.

# Sustainability Management

## Board Statement

The Board of the Company and all Directors confirm that this report contains no false or misleading statements or material omissions, and make the following statement regarding the Board’s ESG oversight and management:



### ESG Management Approach and Strategy

The Board continues to monitor major global ESG trends and, in light of the Company’s current development plans, identifies relevant risks and opportunities and updates the management approach and strategy when necessary to ensure that the Company’s ESG philosophy keeps pace with the times. The Board and the ESG Working Group have carried out active management of key topics such as product quality and safety, customer service, R&D and innovation, business ethics, compliant employment, employee development and training, and this report focuses on how these issues are managed.

### ESG Risk Management

The Board recognizes that it bears overall responsibility for the Company’s risk management activities and for managing material ESG-related risks. The Board actively communicates with stakeholders, assesses and prioritizes the materiality of ESG issues, identifies related risks and opportunities, and updates management approaches and strategies where necessary. We have incorporated ESG risks (including climate-related risks) into the Company’s risk assessment and control system. Taking into account the likelihood of climate risks and their potential impact on the Company, we have, with reference to the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), carried out climate risk identification to comprehensively review the climate-related physical and transition risks faced by the Company, and plan to formulate response measures for identified key risks so as to enhance the Company’s climate resilience. For details, please refer to the section headed “Climate Change” in this report.

### Target Setting and Progress Review

The Board is responsible for overseeing progress against the environmental targets set by the Company and reviewing related performance. We have established ESG strategies and targets to review and manage the Company’s impacts on ESG and have integrated the concept of sustainable development into relevant operational levels. The Company’s ESG Working Group regularly reviews ESG targets, progress and completion status.

In reviewing the progress of ESG-related targets and metrics, the Board also considers how such targets and metrics support the Company’s business development and risk management. In particular, targets and metrics relating to product quality and safety, compliant operations, employee development, resource use efficiency and environmental compliance are closely linked to the Company’s R&D, manufacturing, commercialization and long-term competitiveness. Through regular reviews of progress against these targets, the Board promotes the integration of sustainability into the Company’s day-to-day operations and medium- to long-term business planning.


In the future, the Board will continue to optimize the Group’s ESG governance, actively respond to stakeholders’ concerns, formulate corresponding action plans, and regularly review the progress of relevant targets to continuously enhance ESG management.

## ESG Governance


The Company has established a three-tier governance structure under which the Board is responsible for oversight, management is responsible for overall coordination, and the ESG Working Group is responsible for specific implementation. As the highest decision-making body for ESG matters, the Board assumes ultimate responsibility for the overall direction, strategy, targets, performance and related disclosures of sustainable development. The Board is responsible for reviewing and overseeing the Company's ESG vision, policies and targets, and for assessing and confirming, at least annually, the material ESG risks and opportunities faced by the Company to ensure that relevant issues are fully identified and properly addressed.

As the key link between the Board's decision-making and the Working Group's execution, management is responsible for translating the ESG strategy formulated by the Board into specific action plans and overseeing the day-to-day operation of the ESG Working Group. Management is also responsible for ensuring the effective operation of processes for the identification, assessment and management of ESG-related risks and opportunities, coordinating cross-departmental resources to support the achievement of ESG targets, and reporting regularly to the Board on the overall progress of ESG work.

The ESG Working Group is composed of heads of various functional departments, covering departments such as the Functional Center, Supply Chain Center and R&D Center. The head of the ESG Working Group is responsible for implementing the tasks assigned by management at the level of specific business units, organising communication meetings, and tracking and assessing the execution of relevant work.



- Approves and reviews the establishment and updates of the Company's purpose, mission or targets related to sustainable development
- Oversees the implementation of the sustainability strategy and coordinates the required resources
- Assesses and confirms the Company's material ESG risks and opportunities
- Oversees the Company's ESG KPIs and evaluates the progress and performance of ESG work
- Reviews and approves the Company's ESG-related information disclosure reports



- Formulates the Company's ESG strategy, targets and medium- to long-term plans
- Formulates the Company's annual ESG work plan
- Organizes the identification and assessment of ESG risks and opportunities and formulates response measures
- Formulates the Company's ESG-related policies and reviews and updates them regularly
- Coordinates cross-departmental resources to support the smooth advancement of ESG work




- Executes the Company's annual ESG work plan
- Organizes stakeholder communication
- Organizes ESG-related training
- Collects and organizes ESG-related data and information, prepares the Company's annual ESG report, and submits it to management for review and then to the Board for consideration and approval prior to disclosure



## Materiality Assessment

The Company attaches great importance to the identification of material ESG issues. Taking into account stakeholder concerns and the Company's operational realities, and with reference to relevant standards such as the ESG Reporting Code of the Hong Kong Stock Exchange, the Company regularly reviews ESG issues that have a material impact on its operations and development. It also assesses and prioritizes the identified material issues based on multi-dimensional information, including expert opinions, peer practices and stakeholder feedback. The results of the materiality assessment are reviewed and confirmed by management and serve as an important basis for the Company's formulation of sustainable development strategies.

### 2025 Edge Medical Materiality Matrix



## Stakeholder Communication


The Company actively engages with stakeholders and, in light of its business characteristics and industry practices, maintains smooth communication channels and responds promptly to the expectations and demands of governments and regulators, shareholders and investors, employees, customers, suppliers, communities and the media through daily communication, regular meetings, information disclosure and various other means, thereby enhancing mutual understanding and trust. During the Reporting Period, the Company maintained communication with key stakeholders through a variety of channels, including day-to-day communication, meetings and exchanges, site visits, supplier assessments and audits, customer complaint and feedback channels, investor communication, employee communication mechanisms and information disclosure, and incorporated key concerns identified during the communication process into ESG issue identification, materiality assessment and day-to-day management.

Key Stakeholders	Governments and Regulators	Shareholders and Investors	Employees	Customers	Suppliers	Communities	Media
<b>Expectations and Demands</b>	<ul style="list-style-type: none"> <li>- Compliant operations</li> <li>- Anti-corruption</li> <li>- Product quality and safety</li> <li>- Environmental protection</li> </ul>	<ul style="list-style-type: none"> <li>- Investment returns</li> <li>- Corporate governance</li> <li>- Risk management</li> <li>- Information disclosure</li> </ul>	<ul style="list-style-type: none"> <li>- Remuneration and benefits</li> <li>- Career development and promotion</li> <li>- A healthy and safe working environment</li> </ul>	<ul style="list-style-type: none"> <li>- Product quality and safety</li> <li>- R&amp;D and innovation</li> <li>- After-sales service</li> <li>- Intellectual property protection</li> </ul>	<ul style="list-style-type: none"> <li>- Product quality and safety</li> <li>- Win-win cooperation</li> <li>- Supply chain management</li> </ul>	<ul style="list-style-type: none"> <li>- Community engagement</li> <li>- Environmental protection</li> <li>- Product quality and safety</li> </ul>	<ul style="list-style-type: none"> <li>- Environmental protection</li> <li>- Community engagement</li> <li>- Information transparency</li> </ul>
<b>Communication and Response Channels</b>	<ul style="list-style-type: none"> <li>- Regulatory oversight</li> <li>- Regular disclosure</li> <li>- Ad hoc reporting</li> <li>- Participation in relevant meetings</li> </ul>	<ul style="list-style-type: none"> <li>- Regular/ad hoc information disclosure</li> <li>- General meetings</li> <li>- Investor exchange activities</li> <li>- Communication by telephone and email</li> </ul>	<ul style="list-style-type: none"> <li>- WeCom</li> <li>- Internal email system</li> <li>- Regular meetings and training</li> </ul>	<ul style="list-style-type: none"> <li>- Daily service communication</li> <li>- Customer complaint channels</li> <li>- Social media</li> <li>- Customer exchanges and visits</li> </ul>	<ul style="list-style-type: none"> <li>- Supplier qualification investigation</li> <li>- Supplier assessment and audit</li> <li>- Supplier communication</li> </ul>	<ul style="list-style-type: none"> <li>- Corporate website</li> <li>- Community activities</li> <li>- Media platforms</li> <li>- Information disclosure</li> </ul>	<ul style="list-style-type: none"> <li>- Media interviews</li> <li>- Information disclosure</li> <li>- Communication by telephone and email</li> </ul>

## Strengthening Governance for Sustainable Growth

Edge Medical strictly complies with the laws, regulations and industry regulatory requirements applicable in the places where it operates. Based on the attributes of the high-end medical technology industry, the Company continues to improve its corporate governance system and internal control and compliance mechanisms, adheres to business ethics and medical ethics, and steadily advances information security and data protection management, ensuring standardized and orderly operation across R&D, manufacturing, registration, promotion and services, thereby laying a solid foundation for sound operations, innovation-driven development and sustainable high-quality growth.

**Aligned with the United Nations Sustainable Development Goals (SDGs)**





# Corporate Governance

In accordance with the Company Law of the People’s Republic of China, the Securities Law of the People’s Republic of China, the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, the Guidelines for Articles of Association of Listed Companies, the Listing Rules, and other laws, regulations, departmental rules, normative documents and the relevant requirements of the securities regulatory authorities in the place where the Company’s shares are listed, and in light of the actual circumstances of the Company, Edge Medical has formulated the Articles of Association to regulate the organization and activities of the Company and to provide the fundamental guidelines for its operations.

The Board of the Company consists of nine Directors, including three executive Directors, three non-executive Directors and three independent non-executive Directors. Directors serve terms of no more than two years and may be re-elected. The Board has established the Audit Committee, the Nomination Committee and the Remuneration Committee. For more information on corporate governance, please refer to the 2025 Annual Report of Shenzhen Edge Medical Co., Ltd.

To better respond to the evolving business environment, we have adopted a Board Diversity Policy and undertake to consider diversity in the appointment of Board members. In the nomination process, we comprehensively consider diversity factors such as gender, age, cultural and educational background, ethnicity, professional experience, skills, independence, knowledge and length of service, so as to ensure an appropriate balance of background, skills and perspectives on the Board.



# Business Ethics

In accordance with the Criminal Law of the People’s Republic of China, the Anti-Unfair Competition Law of the People’s Republic of China, the Company Law of the People’s Republic of China, the Anti-Monopoly Law of the People’s Republic of China, applicable overseas anti-corruption laws, the Basic Standard for Enterprise Internal Control, the Articles of Association, and other relevant laws, regulations and policies, Edge Medical has formulated the Guidelines on Anti-Fraud, Anti-Corruption and the Prevention of Illegal and Criminal Conduct, continuously improved the integrity and compliance management mechanism, and strengthened the prevention and governance of fraud, corruption and other illegal or non-compliant acts, with a view to fostering an honest, positive, healthy, well-regulated and orderly working environment and corporate culture and effectively safeguarding the legitimate rights and interests of the Company, shareholders and employees. At the same time, the Company extends compliance and integrity requirements to external cooperation management by incorporating compliance and integrity clauses into contracts with suppliers and other partners, clarifying each party’s responsibilities in lawful operations, self-discipline and business ethics, and promoting the development of an honest, transparent and well-regulated cooperation ecosystem.

The Company has established an anti-corruption system led by management, jointly advanced by relevant functional departments and implemented across business units. Focusing on key aspects such as integrity culture building, compliance communication and training, reporting acceptance, clue verification, issue handling and accountability, the Company continuously strengthens the prevention and control of fraud and corruption risks and enhances the standardization and effectiveness of anti-corruption management. All departments strictly implement the Company’s integrity and compliance requirements, strengthen day-to-day supervision and risk prevention, and actively cooperate with relevant investigations and rectification work, jointly fostering an organizational atmosphere of honest operations and clean conduct.

The Company has established sound whistleblower protection and reward measures, requiring personnel responsible for accepting reports and complaints or investigating fraud cases (including relevant departments and personnel assisting with investigations) not to disclose any information or materials relating to whistleblowers to any department or individual without authorization, and not to show reports or other materials involving whistleblowers’ personal information to the department or person under investigation, so as to ensure that complainants and whistleblowers are strictly protected while assisting in investigations.

The Company has established internal legal supervision and audit supervision systems as well as reward and disciplinary provisions, and has set up specialized bodies to coordinate relevant functional departments, strengthen the ability to detect and address unhealthy practices, carry out anti-corruption training, and leverage the labour union and internal communications functions to reinforce positive messaging and foster a positive, healthy cultural environment and a caring workplace atmosphere, thereby continuously enhancing employees’ awareness of anti-corruption.

## Reporting Channels



WeCom, OA and internal email

Audit Department / Legal Department



### Address

Room 1901, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC

During the Reporting Period, the number of concluded corruption lawsuits against the Company or its employees was zero. The anti-corruption training provided to the Board and employees is set out in the table below:

Indicator	Unit	2025
Anti-corruption training sessions provided to Directors	session(s)	1
Number of Directors participating in anti-corruption training	person(s)	9
Anti-corruption training sessions provided to employees	session(s)	96
Number of employees participating in anti-corruption training	person(s)	191

## Medical Ethics

Edge Medical attaches great importance to medical ethics and animal welfare, and promotes the development of medical technology innovation in a responsible manner. As an enterprise engaged in the R&D and manufacture of surgical robots, the Company embeds ethical requirements throughout key links such as product R&D, clinical trials, clinical application, data management and commercialization, with a focus on issues including the safety of subjects and patients, the authenticity of clinical data, and the protection of personal health information, so as to ensure that innovative technologies better serve clinical practice and patients on a lawful, compliant, scientific and prudent basis.

In clinical trials, clinical evaluation and related research activities, the Company places the protection of subjects' rights and interests as a prerequisite, values the protection of subjects' rights to be informed, to make autonomous choices, to privacy and to safety, and requires relevant research to be conducted on a lawful and compliant basis and subject to ethics review approval. At the same time, the Company continues to strengthen process management for clinical research, standardize the collection, transmission, storage and use of data, ensure that research activities are conducted in a regulated and orderly manner and that data are authentic and complete, and effectively safeguard the legitimate rights and interests of subjects.

In pre-clinical research, product validation and related scientific research activities, the Company places importance on animal welfare protection, strictly complies with applicable laws, regulations and laboratory animal management requirements, and prudently carries out related research in line with the principles of Replacement, Reduction and Refinement. For animal testing that is indeed necessary, the Company continues to standardize testing procedures and operational requirements and actively cooperates with qualified institutions, striving to improve the level of animal welfare protection while ensuring scientific rigor.

During the Reporting Period, the Company's relevant clinical trials and research activities completed ethics review procedures as required, and no incidents involving violations of medical ethics or animal welfare requirements occurred.

## Information Security

As a company deeply engaged in China's homegrown surgical robotics sector, we recognize that data security is critical to the Company's development. The Company strictly complies with relevant laws and regulations, including the Cybersecurity Law of the People's Republic of China, the Data Security Law of the People's Republic of China, the Personal Information Protection Law of the People's Republic of China, the Regulation on Network Data Security Management, and the Measures for Security Assessment for Outbound Data Transfers, and protects the information security of stakeholders such as customers, employees and third parties in accordance with laws and regulations.

We are committed to protecting the privacy and security of customers, employees and third parties. We have implemented policies and protocols to ensure data and information security, optimize data governance, protect the interests of customers, employees and third parties, and ensure compliance in all material respects with applicable laws and regulations. The Company engages external professionals to review and update our internal control policies and strategies, ensure the implementation of data protection policies and maintain ongoing compliance in all material respects with applicable laws and regulations.

### ● Access Control

Sensitive data is encrypted, and access rights are managed by role on a tiered basis in line with the principle of minimum necessity to strictly prevent unauthorized access and data leakage.

### ● Enhancing Security Awareness

Information security training is conducted regularly to strengthen information security and confidentiality awareness and build a strong all-staff line of defense.



# Integrity and Innovation, Quality for the Future

Edge Medical remains committed to the principle of “original innovation”, continuously invests in research and development resources, protects intellectual property rights, and constantly improves its quality management system and responsible marketing mechanism, so as to provide customers and users with high-quality products and services and work with all partners to advance the development of medical technology.

Aligned with the United Nations Sustainable Development Goals (SDGs)



# Quality Management


Edge Medical is committed to safeguarding patient safety through continuous improvement of its quality management system to meet evolving regulatory standards, and regularly collects feedback from medical institutions and end users to enhance product safety and patient experience. During the Reporting Period, there were no sold or shipped products subject to recall for safety and health reasons.

## Product Quality Management System

The Company always places patient safety first. In strict compliance with relevant laws and regulations such as the Regulations on the Supervision and Administration of Medical Devices, the Good Manufacturing Practice for Medical Devices and the Measures for the Administration of Medical Device Recalls, it has established a quality management system covering the entire product life cycle, together with supporting procedures and systems. The Company has passed inspection under the Good Manufacturing Practice for Medical Devices (GMP) and obtained ISO 13485 quality management system certification.

In terms of product quality control, the Company has formulated and implemented the Inspection and Release Control Procedure, under which strict quality controls are applied to procured raw materials, externally sourced products and self-manufactured products at each stage including incoming inspection, production process control, finished goods inspection and release, and re-inspection of returned products, thereby ensuring the compliance and effectiveness of the inspection process and safeguarding product quality and patient safety from the source and throughout the manufacturing process.

At the same time, the Company has formulated the Internal Audit Control Procedure to ensure that audits of the operation of the quality management system are organized within the prescribed time frame, so as to evaluate whether the Company's quality management system operates in compliance with laws, regulations and the requirements of relevant parties and to ensure the compliance and effectiveness of the quality management system (QMS).



## Product Recall

The Company has formulated the Product Recall Control Procedure to standardize product recall processes, strengthen medical device supervision and administration, control defective medical device products, eliminate potential safety hazards, ensure the safety and effectiveness of medical devices, and protect human health and life.

In accordance with relevant requirements of the national medical products regulatory authorities on medical device adverse event monitoring, product recalls and advisory notices, the Company has formulated and implemented the Control Procedure for Medical Device Adverse Event Monitoring and Re-evaluation to conduct continuous adverse event monitoring and risk assessment of the Company's domestically marketed products. Where a product recall is required upon approval, recall information will be released to relevant customers through channels such as the marketing center and reported to the competent medical products authorities as required. Meanwhile, the Quality Department tracks the implementation of the recall and product disposition throughout the process to ensure that all products subject to recall are properly handled and that potential risks to patients are minimized.

## Quality Culture Development

The Company places great importance on quality culture development and insists on integrating quality principles into full life-cycle product management and daily operations, continuously fostering a management atmosphere in which "everyone values quality, every process is quality-controlled, and continuous improvement enhances quality." The Company has formulated a Quality Manual covering the full process of design and development, procurement, manufacturing, inspection, sales and after-sales service delivery for all products, as well as quality monitoring, providing clear guidance for institutionalized, standardized and normalized quality management. The Company upholds the quality policy of "creating intelligent, dexterous, safe and reliable surgical robot products with a philosophy of excellence and a pioneering spirit of exploration, to empower physicians and benefit patients," and continues to strengthen quality accountability awareness among all employees so that quality requirements are embedded in all business links and key positions.

In light of actual business needs, the Company organizes a series of quality training sessions focusing on quality awareness enhancement, job operation standards, key process controls and quality risk prevention, continuously improving employees' theoretical understanding and practical capabilities in product quality management and promoting the transformation of quality requirements from institutional mandates into shared understanding and conscious action by all staff. During the Reporting Period, the Company continued to provide quality training to production employees, further consolidating the foundation for frontline quality management and enhancing process control and delivery quality.

At the same time, the Company has established quality objectives for key links such as supplier management, production processes and customer service, and continuously tracks the achievement of these objectives, prompting relevant departments to strengthen quality accountability and collaborative improvement, thereby enhancing the systematic nature and effectiveness of quality management. Going forward, the Company will continue to deepen quality culture development, further optimize the quality management system to higher standards, and provide safer, more reliable and more stable surgical robot products and services for clinical practice.



# Customer Service

Guided by a service philosophy centred on customers and patients, Edge Medical has established customer service management systems such as the Customer Feedback Control Procedure and the Customer Satisfaction Survey Control Procedure. The Company regularly conducts customer satisfaction surveys, systematically collects opinions and improvement suggestions from medical institutions and end users, and incorporates such information into product optimization and service improvement, thereby continuously enhancing product safety and user experience.

### During the Reporting Period

the Company received 3 complaints relating to products and services, all of which were properly handled, with a complaint resolution rate of

100%



# Technological Innovation

Adhering to the principle that technological development should be rooted in original innovation, Edge Medical continues to invest in R&D personnel and capital, strengthen cooperation with research institutions and universities, and maintain a high-caliber cross-disciplinary R&D team comprising several hundred members. With more than a decade of technological accumulation and development, the Company has independently mastered all core technologies involved in surgical robots, including the six platform technologies of robot body design, multiple degrees of freedom (DOF) minimally invasive mechanism design, hardware-specific electrical system engineering, control algorithm and software engineering, imaging techniques and system integration engineering. On this basis, it has established a rich and comprehensive product portfolio. The Company has also established a complete barrier of proprietary intellectual property, and continues to lead the innovative development and clinical application of high-end surgical robots made in China. Edge Medical has built a “three-in-one” surgical solution integrating multi-port, single-port and remote systems, continuously advancing surgical progress through technological innovation, promoting the sharing of advanced surgical technologies and quality medical resources worldwide, and enabling Chinese medical innovation to benefit more patients.

In terms of industry-academia-research cooperation, we actively carry out strategic cooperation with universities and medical institutions, including but not limited to jointly applying for research projects, co-authoring academic papers and establishing remote training centers, so as to better understand user needs, promote product innovation and benefit society. According to incomplete statistics, Edge Medical’s Edge Multi-Port Endoscopic Surgical Robot has supported partner hospitals in publishing more than 20 high-quality academic papers in China; Edge Medical also joined hands with the PLA General Hospital, Tsinghua University and others to make major progress in autonomous suturing technology.

As of the end of the Reporting Period, the Company has received technological innovation awards including the Second Prize of the 2023 National Science and Technology Progress Award and the First Prize of the 2021 Guangdong Provincial Science and Technology Progress Award, and has been recognized as a Specialized, Sophisticated, Distinctive and Innovative “Little Giant” Enterprise and obtained the High-tech Enterprise Certificate.



National Science and Technology Progress Award



In August 2025, Edge Medical participated in China-Hospeq 2025, showcasing its surgical robotic products and related application practices.

## Intellectual Property Protection

The Company has established a dedicated intellectual property department responsible for patent portfolio planning, application and maintenance, thereby ensuring that all of the Company's intellectual property rights are protected lawfully and in compliance with regulations. The Company has also formulated intellectual property incentive measures and grants acceptance bonuses and remuneration once patent applications are accepted.

### As of the end of the Reporting Period

the Company had

**736** granted patents and patent applications worldwide



the Company had registered

**30** trademarks in China

and

**18** overseas

with

**2** trademark applications in China

and

**1** overseas under review

Through continuous patent portfolio development, trademark protection and trade secret management, the Company has established a relatively comprehensive intellectual property protection system, providing important support for core technology innovation and product commercialization.

## Responsible Marketing


In accordance with relevant requirements such as the Advertising Law of the People's Republic of China and the Regulations on the Supervision and Administration of Medical Devices, the Company has formulated the Administrative Measures for News and Publicity, established a three-level review mechanism consisting of business departments, management departments and leadership, standardized the Company's external publicity activities, and ensured that publicity content is lawful and truthful.



# Growing Together, Empowering Our People

Edge Medical believes that talent is fundamental to enterprise development. The Company consistently safeguards the lawful rights and interests of employees, continuously optimizes its talent management mechanism and development system, provides competitive remuneration and benefits, protects employees' occupational health and safety, and builds a harmonious, equitable, safe and healthy working environment.

Aligned with the United Nations Sustainable Development Goals (SDGs)



# Employee Rights and Interests

The Company always puts employee rights and interests first, strictly complies with national laws and regulations, continuously improves employee management mechanisms, effectively safeguards the lawful rights and interests of employees, and is committed to building standardized, orderly, fair and harmonious labor relations.

## Compliant Employment

The Company strictly complies with relevant laws and regulations such as the Labor Law of the People's Republic of China, the Labor Contract Law of the People's Republic of China, the Law of the People's Republic of China on the Protection of Minors and the Provisions on the Prohibition of Child Labor. Upholding the principles of lawful employment, standardized management and equal employment, the Company continuously improves its processes for recruitment and hiring, execution of labor contracts, verification of employee information and day-to-day labor management, thereby effectively safeguarding employees' lawful rights and interests. The Company undertakes not to discriminate against any applicant or employee on grounds such as race, religion, gender, age, physical condition, marital status, health condition or political affiliation in recruitment, hiring, promotion or daily management, respects and protects employees' personal privacy, and strives to create a fair, just, standardized and orderly employment environment.

At the same time, the Company firmly opposes any form of child labor and forced labor. It strictly implements identity and age verification procedures, carefully verifies applicants' information and prevents illegal employment risks at the source. If any suspected child labor, forced labor or other non-compliant practices are identified, the Company will immediately suspend the relevant arrangement, promptly initiate investigation and rectification procedures, and take necessary support and remedial measures in accordance with the law to effectively safeguard the lawful rights and interests of the persons concerned. During the Reporting Period, the Company did not encounter any incidents involving child labor, forced labor or other employment violations.




## Diversity, Equality and Inclusion


The Company adheres to a fair, just and open talent philosophy. In line with the principles of “appointing people based on merit, open recruitment, internal candidates first and merit-based hiring,” it has formulated the Recruitment Management System and widely attracts various professional talents through diverse channels such as internal promotion, online recruitment, dedicated recruitment fairs, internal employee referrals, executive search firms and campus recruitment. In the recruitment and selection process, the Company focuses on professional qualifications, practical experience, overall capabilities and development potential required by the role, continuously broadening talent sources and optimizing its talent structure to provide solid talent support for the Company’s steady development and enhancement of innovation capabilities.

The Company values the creation of an equal and inclusive workplace, respects individual differences among employees and strives to provide fair career development opportunities for talent from different backgrounds and professional fields. In recruitment, promotion, training and job allocation, the Company adheres to a capability- and performance-oriented approach, promoting a standardized and orderly talent development mechanism with equal opportunities and fully stimulating employees’ potential and organizational vitality. The Company believes that a diverse workforce and an inclusive organizational environment are important foundations for enhancing innovation capability, strengthening team collaboration and achieving sustainable development.


As of the end of the Reporting Period, the Company had a total of 602 employees. The breakdown by gender, age, region, educational attainment and employment type is as follows:



	Count	Turnover Rate
30 and below	183	31.69%
30-50	403	24.81%
50 and above	16	25.00%



	Count	Turnover Rate
Master’s degree or above	168	/
Bachelor’s degree	240	/
Associate degree or below	194	/



	Count	Turnover Rate
Male	420	27.86%
Female	182	24.73%



	Count	Turnover Rate
Within Guangdong Province	499	26.05%
Other regions in China outside Guangdong Province	103	31.07%




	Count	Turnover Rate
Full-time	602	/
Part-time	0	/

## Remuneration and Benefits

The Company has established a series of systems, including the Position Grade (Remuneration) Management Measures and the Employee Benefits Management Provisions. Based on the principles of internal and external fairness and incentive priority, it adopts a remuneration strategy combining hybrid and broadband structures, and is committed to building a transparent, fair and market-oriented remuneration management system to achieve dynamic salary growth and ensure that remuneration matches job value, individual contribution and strategic development.

In terms of benefits, the Company contributes to social insurance and the housing provident fund for employees in accordance with the law, provides annual health check-ups, and purchases commercial accident insurance and health insurance to continuously enhance employee protection. At the same time, the Company, taking into account employees’ actual needs, provides diversified benefits such as holiday gifts, work subsidies, transitional accommodation for fresh graduates joining the Company and team-building activities, thereby continuously enhancing employees’ sense of gain, belonging and cohesion and creating a warm, secure and energetic working environment to support the mutual growth of employees and the enterprise.

### Edge Medical Benefits System



# Employee Development

The Company attaches great importance to employee growth and career development, continuously improves its training and capability-building mechanism, and carries out multi-level and targeted training activities in light of employees' development stages and job requirements, striving to build a sound growth platform for employees and promote mutual development between employees and the Company.

Through new employee training, job skills enhancement training and various thematic training programs, the Company helps employees deepen their understanding of corporate culture, business processes, job responsibilities and management requirements, and continuously improve their professional capabilities, job performance and compliance awareness. For key positions such as production roles, the Company continues to strengthen professional skills and standardized operation training according to actual job needs, thereby supporting employees in continuously enhancing their job competence. During the Reporting Period, a total of 410 employees participated in training, with aggregate training hours reaching 2999.50 hours.

Category		Percentage Trained	Average Training Hours (hour(s))
By Gender	Male	60.00%	6.61
	Female	86.81%	8.45
By Employee Category	Middle and Senior Management	22.22%	4.19
	General Staff	71.02%	7.38



The Company organized the “Smart Edge, Starry Future” centralized induction training program for 2024 fresh graduates, establishing a systematic onboarding and development pathway for the new generation of talent and further strengthening the Company’s talent pipeline.



# Employee Safety

The Company upholds the safety principle of “prevention first and people-oriented,” strictly complies with national safety laws and regulations, continuously improves occupational health and safety management standards, and effectively safeguards the life safety and physical health of employees.

## Production Safety

In strict compliance with laws and regulations such as the Work Safety Law of the People’s Republic of China, the Company has formulated the Safety Production and Risk Management System and established a sound work safety management system. The Company implements a department-head accountability system, signs annual safety responsibility letters and establishes a safety risk management list, regularly carries out risk identification and assessment, and classifies and manages safety risks; conducts daily safety inspections and special inspections before holidays, issues rectification notices for identified hazards and tracks their implementation; and provides safety training and assessments; and personnel engaged in special operations and key equipment operation positions are required to hold relevant certificates. At the same time, the Company implements 5S management in office areas to create a safe and tidy office environment and fully safeguard safe production conditions for employees.



## Occupational Health

The Company effectively implements the prevention and management of occupational disease hazards and protects employees’ health rights and interests in all respects through annual employee health check-ups, occupational health monitoring, provision of labor protection supplies and mental health care. During the Reporting Period, the number of lost days due to work-related injuries was 42, and there were no employee fatalities due to work-related injuries in the past three years.

### ➔ Annual Health Check-up



Free annual health check-ups are organized for employees, with special occupational disease examinations arranged for employees in special positions.

### ➔ Provision of Labor Protection Supplies



Production employees are equipped with personal protective equipment such as sterile garments, gloves and caps to ensure adequate occupational protection.

### ➔ Occupational Health Monitoring



Employees working in hazardous environments are regularly subject to occupational health monitoring in accordance with the law, and assessment reports on the current status of occupational disease hazards are issued.

### ➔ Office Environment Assurance



Office desks and chairs fully take ergonomics and comfort into account to provide employees with a good office environment.

### ➔ Employee Mental Health Care



Establish multiple communication and complaint feedback channels, and pay attention to the mental health of employees.

## Care and Communication

The Company values employee care and internal communication. Through diversified activities and smooth feedback mechanisms, it continuously enhances employees' sense of belonging, happiness and cohesion, and fosters a positive and healthy corporate culture.

### Democratic Communication

The Company values employee communication and the protection of rights and interests, encourages positive interaction between employees and all levels of the organization, and continuously establishes and improves diversified communication mechanisms so as to effectively safeguard employees' rights to know, participate and supervise, ensuring that employee demands can be effectively conveyed and responded to in a timely manner. The Company has established a labour union to coordinate employee welfare-related work, and employees may provide feedback and express demands through the union's dedicated telephone line or email. In addition, the Company has set up dedicated reporting mailboxes and hotlines to provide smooth channels for employees to raise issues, make suggestions and report violations, thereby fostering an open, transparent, standardized, orderly, mutually trusting and inclusive communication atmosphere.

### Employee Care

In accordance with the Employee Benefits Management Provisions, the Company continuously improves its employee benefits system and carries out diversified welfare activities focusing on holiday care, daily care and team building, integrating humanistic care into various scenarios of employees' work and life. The Company organizes a variety of care activities in line with traditional festivals, employee growth milestones and team interaction needs, and provides necessary support for employees in need, continuously enhancing employees' sense of gain, belonging and happiness. At the same time, the Company encourages departments to organize team-building activities based on actual conditions in order to strengthen team cohesion and collaboration awareness, and strives to create a warm, harmonious, positive and belonging-oriented workplace atmosphere.



# Advancing Low-carbon Development, Fulfilling Our Responsibilities

Edge Medical earnestly fulfills its environmental protection responsibilities, actively responds to climate change, continuously develops its environmental management system, improves resource use efficiency, strictly regulates emissions management, and is committed to achieving harmonious coexistence between corporate development and the natural environment.

Aligned with the United Nations Sustainable Development Goals (SDGs)



# Climate Change

The Company actively responds to China’s “dual carbon” goals and attaches great importance to the risks and opportunities brought by climate change. With reference to the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), it has built a climate change management system across four dimensions—governance, strategy, risk management, and metrics and targets—to continuously enhance climate resilience and promote green and low-carbon transformation.

## Governance

The Company continuously monitors the impacts of domestic and overseas energy- and carbon-related policies and regulations on the medical device industry and business operations. In accordance with the Stock Exchange’s requirements on climate-related disclosures, it continues to improve its climate change management system and strengthen climate governance responsibilities. The Board is fully responsible for the oversight and management of climate-related issues and ensures that such issues are systematically incorporated into the Company’s ESG governance framework; relevant departments integrate climate-related requirements into day-to-day management systems and business processes, continue to implement specific tasks relating to climate change risk management, and advance the execution of the climate strategy. During the Reporting Period, the Company conducted systematic identification and analysis of climate-related risks and opportunities, laying a foundation for effective climate action.

## Strategy

Taking into account factors such as operating conditions, industry trends and environmental conditions, the Company uses climate scenario analysis to assess the potential impacts of climate-related risks and opportunities, preliminarily formulates a list of climate-related risks and opportunities, and develops corresponding response measures.

Risk Category	Risk Description and Potential Impact on Edge Medical’s Business Model and Value Chain	Response Measures
 Physical Risks	<b>Acute Risks</b> Extreme weather such as typhoons and floods may affect the operational stability of the Company’s infrastructure (such as manufacturing and R&D facilities), leading to supply interruptions, production interruptions and other issues, thereby increasing operating costs and the maintenance costs of assets, equipment and facilities.	Strengthen monitoring and early warning for extreme weather, improve emergency response plans and business continuity management; enhance flood prevention, seepage prevention and protection of key equipment at facilities; optimize supply chain layout and prepare reserves of critical materials.
	<b>Chronic Risks</b> Long-term high-temperature and high-humidity weather may increase the operating load of air conditioning, dehumidification and clean environments, pushing up energy consumption and operating costs and affecting employee health, production efficiency and the storage stability of precision components.	Improve energy management and environmental monitoring systems, enhance temperature and humidity control efficiency, strengthen employee health management, and optimize the storage conditions of raw materials and precision components.
 Transition Risks	<b>Regulatory Risks</b> As “dual carbon” policies, green manufacturing, environmental information disclosure and green procurement requirements continue to advance, the Company may face higher costs of compliance management, energy-saving retrofits and data disclosure.	Continuously track changes in climate and environmental policies; improve internal systems and data management mechanisms; and integrate climate and environmental compliance requirements into procurement, R&D, manufacturing and disclosure processes.
	<b>Technology Risks</b> As the Company’s products are high-end medical devices, if new materials, new processes or energy-saving technologies are introduced to support low-carbon transition, there may be risks such as R&D failure, prolonged validation cycles or higher costs for registration changes.	Take into account low-carbon requirements as well as product safety and effectiveness in R&D project initiation and change review; strengthen collaboration among R&D, quality, regulatory and supply chain functions; and steadily promote the application of green technologies.
	<b>Market Risks</b> Hospital customers, overseas markets and partners are increasingly focused on green manufacturing, product energy efficiency, carbon footprints and the environmental performance of supply chains. If the Company fails to respond adequately, its market competitiveness and business expansion may be affected.	Pay attention to customer needs and industry trends, optimize product strategies, strengthen green supply chain management and raw material risk analysis, and improve communication on the environmental value of products throughout their life cycle.
	<b>Reputational Risks</b> If the Company performs inadequately in environmental management, climate response or information disclosure, or if deliveries and services are affected by extreme weather, the trust of customers, investors and partners may be weakened, affecting brand image.	Strengthen climate-related information disclosure and stakeholder communication; improve customer service and public opinion response mechanisms under emergencies; and continuously enhance green operational management.

Opportunity Category	Opportunity Description and Potential Impact on Edge Medical's Business Model and Value Chain	Response Measures
 <p><b>Products and Services</b></p>	<p>Against the backdrop of green hospital development, medical equipment upgrades and low-carbon development, market demand for efficient, energy-saving and sustainable medical devices and services continues to grow. The Company can leverage the advantages of its surgical robot products to enhance market competitiveness and achieve long-term growth.</p>	<p>Integrate green and low-carbon concepts into the entire process of product design, manufacturing and services; improve product energy efficiency, maintainability and resource utilization efficiency; and continue to launch products and solutions that meet market demand.</p>
 <p><b>Resource Efficiency</b></p>	<p>By continuously promoting green operations through energy-saving technologies, procurement of green electricity, self-generated green electricity and resource recycling and reuse, the Company can improve resource utilization efficiency, reduce resource consumption and waste generation in production, and lower operating costs.</p>	<p>Use efficient equipment and energy-saving processes, optimize air-conditioning, clean room and environmental control systems, advance energy consumption monitoring and intelligent management, explore clean energy applications, and continuously improve resource utilization efficiency.</p>

## Risk Management

The Company integrates climate risk management into its daily operating system. Through regular communication with stakeholders, it continues to monitor climate-related policy trends and industry practices. In terms of resource conservation and emissions reduction, the Company actively carries out energy-saving, consumption-reduction and emissions-reduction management initiatives to promote low-carbon transformation in operations. At the same time, the Company incorporates climate risk identification into its existing risk management process and continues to monitor operating links that may be affected by extreme weather to ensure timely responses.

## Metrics and Targets

The Company's greenhouse gas emissions mainly arise from direct emissions (Scope 1) generated by gasoline consumed in production and operations and indirect emissions (Scope 2) generated from purchased electricity. In accordance with prevailing industry practices and greenhouse gas accounting methodologies, the Company strictly monitors its greenhouse gas emissions. During the Reporting Period, the Company identified greenhouse gas emission sources within its operational control boundary and calculated its 2025 greenhouse gas emissions data, laying the groundwork for climate change mitigation and adaptation, as well as for developing reasonable climate policies and emissions reduction pathways.

Indicator	2025	Unit
GHG Emissions (Scope 1) <sup>1</sup>	36.62	tCO <sub>2</sub> e
GHG Emissions (Scope 2) <sup>2</sup>	905.82	tCO <sub>2</sub> e
GHG Emissions (Scope 3) <sup>3</sup> (covering business flights and waste paper disposal only)	626.61	tCO <sub>2</sub> e
Total GHG Emissions	1,569.05	tCO <sub>2</sub> e
GHG Emission Intensity per RMB Million of Revenue	3.44	tCO <sub>2</sub> e

<sup>1</sup>According to Appendix 2 to How to Prepare an ESG Report published by the Stock Exchange, Scope 1 greenhouse gas emissions refer to direct emissions generated from equipment and operations owned or controlled by the Company, which primarily arise from gasoline consumption by our vehicles.

<sup>2</sup>According to Appendix 2 to How to Prepare an ESG Report published by the Stock Exchange, Scope 2 greenhouse gas emissions refer to purchased electricity consumed within the Company. The emission factor adopted for purchased electricity is the national average carbon dioxide emission factor for electricity in 2023, sourced from the 2023 Electricity Carbon Dioxide Emission Factor issued by the General Office of the Ministry of Ecology and Environment on December 31, 2025.

<sup>3</sup>Scope 3 greenhouse gas emissions primarily include greenhouse gas emissions arising from waste generated in operations (Category 5) and business travel (Category 6).

# Environmental Management


In strict compliance with laws and regulations such as the Environmental Protection Law of the People’s Republic of China and the Environmental Impact Assessment Law of the People’s Republic of China, the Company has formulated and implemented the Environmental and Social Responsibility Management System. In daily operations, the Company emphasizes resource conservation and pollution prevention, and enhances environmental awareness among all employees by providing environmental protection-related training. At the same time, it regularly inspects the implementation of environmental protection policies and promptly rectifies non-compliant behavior to ensure the effective operation of the environmental management system. During the Reporting Period, the Company did not experience any major environmental risk incidents or any violations of environmental protection-related laws and regulations.

In light of the Company’s business nature, the Company is principally engaged in the R&D, assembly and manufacturing, office operations and related service activities of surgical robots. Material impacts on the environment and natural resources primarily arise from electricity consumption, water consumption, the use of packaging materials, and the generation of hazardous and non-hazardous waste in the course of R&D, production and office operations. To mitigate the impacts of operating activities on the environment and natural resources, ongoing measures have been implemented in areas including energy conservation and consumption reduction, water management, optimisation and recycling of packaging materials, waste segregation and management, compliant disposal of hazardous waste, enhancement of employees’ environmental awareness, and continuous improvement of environmental management systems.

## Environmental Management Targets

Commitment/Target	2025 Performance
100% annual wastewater discharge compliance rate	Achieved
100% compliant disposal rate for solid waste	Achieved
100% compliant disposal rate for hazardous waste	Achieved
2025 energy consumption will not be materially higher than that of 2024	Achieved
Using 2024 as the base year, reduce water intensity (tons/RMB million of revenue) by 20% before 2030	Achieved

To ensure the efficient operation of the environmental management system, the Company has established a three-tier environmental governance structure comprising the Board, management and the ESG Working Group, improved top-down accountability transmission and oversight mechanisms, implemented environmental management measures, and regularly reports to the Board.



# Resource Use

While advancing business development, the Company attaches great importance to resource conservation and recycling, implements energy saving and emissions reduction across all aspects of production and operations, actively develops and uses energy-efficient products, promotes a circular economy, reduces pollutant emissions and improves overall resource utilization efficiency.

## Energy Management

In accordance with laws and regulations such as the Energy Conservation Law of the People’s Republic of China, the Company has formulated internal documents including the Environmental and Social Responsibility Management System and the Administrative Management System to regulate energy use. The Company’s principal energy consumption includes purchased electricity and gasoline. Based on its current energy use profile, the Company emphasizes cultivating employees’ awareness of energy conservation by advocating that employees switch off electrical appliances when leaving work or being away for extended periods, turn off or lock computer screens when not in use for a long time, use personal office supplies on an as-needed basis to reduce unnecessary consumption, and promptly switch off air-conditioning, lighting and projection equipment after meetings. The Company also prohibits the use of air-conditioning with doors or windows open, thereby ensuring that energy-saving and consumption-reduction measures are effectively implemented.

Indicator	2025	Unit
Total energy consumption	223.32	tce
Energy intensity	0.49	tce/RMB million of revenue
Direct energy	Gasoline	13,522.00 L
Indirect energy	Total purchased electricity	1,707,158.70 kWh

## Water Resource Management

The Company strictly complies with laws and regulations such as the Water Law of the People’s Republic of China and continuously optimizes water resource management in line with its operational realities to ensure reasonable use and effective protection of water resources. The Company’s daily water is sourced from the municipal pipe network, and water supply channels are stable and controllable, with no material water sourcing risk; nor are its operating locations situated within drinking water source protection zones. At the same time, the Company actively promotes water-saving awareness and implements water conservation measures to continuously reduce water waste and improve utilization efficiency. During the Reporting Period, the Company did not encounter any issues in sourcing water that is fit for purpose for its operations.

Indicator	2025	Unit
Total water consumption	4,136	m <sup>3</sup>
Water intensity	9.08	tons/RMB million of revenue

## Packaging Materials Management

In accordance with laws and regulations such as the Circular Economy Promotion Law of the People’s Republic of China, the Company adheres to the principles of “reduce, reuse and recycle” and continues to explore ways to optimize packaging materials. In the product packaging process, the Company recycles and reuses wooden frames for certain equipment to extend the useful life of packaging materials and reduce one-off consumption. In packaging design, the Company continuously optimizes structural solutions and gives priority to environmentally friendly materials and designs, technologies and raw materials that save energy and reduce waste, thereby reducing environmental impacts at the source.

Indicator	2025	Unit
Total packaging materials used for manufactured finished products	99	ton(s)
Of which, wood	68	ton(s)
Cartons	31	ton(s)
Packaging material consumption intensity	0.22	tonnes/RMB million of revenue

# Emissions

In accordance with relevant national laws and regulations, the Company has established and implemented a classified emissions management mechanism to standardize the disposal procedures for wastewater and waste and to ensure that all types of emissions are properly handled. During the Reporting Period, the Company's operations mainly consisted of medical device assembly, research and development and office administration, and there were no material regulated air emission processes. Apart from the relevant emissions arising from a small number of vehicles in use, the Group did not identify any other material air emission sources.

## Wastewater Management

The Company strictly complies with relevant laws and regulations such as the Water Pollution Prevention and Control Law of the People's Republic of China, attaches great importance to wastewater management in the course of operations, and actively fulfils its environmental protection responsibilities. Through ongoing daily management, the Company ensures that its wastewater discharge complies with national and local environmental protection requirements. During the Reporting Period, the Company had no incidents of non-compliant wastewater discharge, and total wastewater discharge amounted to 4 tonnes.

Taking into account the Company's operational characteristics, current emissions management targets mainly focus on compliance management and source control. During the Reporting Period, management efforts continued to focus on maintaining compliant wastewater discharge, standardizing waste disposal, strengthening vehicle use management and advancing routine energy conservation and consumption reduction, so as to reduce emissions impacts arising from operations. Through measures such as routine monitoring, classified management, compliant disposal, employee environmental awareness campaigns and the implementation of management systems, progress was made toward these emissions management targets.

## Waste Management

In accordance with laws and regulations such as the Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste, the Company standardizes the management of various types of waste generated during operations and formulates corresponding treatment methods according to the nature of the waste so as to reduce impacts on the ecological environment.

For non-hazardous waste such as cardboard and domestic waste, the Company implements classified collection and uniformly entrusts municipal sanitation departments or professional institutions with compliant disposal. At the same time, the Company actively promotes green office practices and, through the Printing Security Management System, implements the principle of "no printing unless necessary," strictly controls printing permissions and establishes approval procedures, thereby reducing paper consumption at the source.

For hazardous waste, given the Company's characteristics as a low-pollution and low-emission enterprise, no high-concentration wastewater or waste liquid is generated during operations, and the relevant low-pollution wastewater and waste liquid are lawfully and compliantly entrusted to qualified third-party institutions for disposal. In addition, medical waste is placed in designated garbage bags, sterilized, and then entrusted to qualified third-party companies for standardized transfer and treatment.



The Company has established waste management targets, including continuously reducing non-hazardous waste generated from day-to-day operations where practicable, minimizing the generation of hazardous waste at source as far as possible, and maintaining 100% compliant disposal of both hazardous and non-hazardous waste. To achieve these targets, the Company has continued to promote green office practices and reduce unnecessary printing, optimize the use and recycling of packaging materials, implement classified collection and management of waste, and lawfully engage qualified third-party institutions to carry out the standardized disposal of hazardous waste and other waste requiring professional treatment.

Indicator	2025	Unit
Total non-hazardous waste	7.15	ton(s)
Total non-hazardous waste generated per RMB million of revenue	0.016	ton(s)
General packaging (wooden frames, cardboard)	4.55	ton(s)
Waste packaging	2.57	ton(s)
Waste light tubes	0.03	ton(s)
Total hazardous waste	0.85	ton(s)
Hazardous waste generated per RMB million of revenue	0.0018	ton(s)
Waste activated carbon	0.3	ton(s)
Production waste (glass bottles/plastic bottles/labware/gloves/masks/ laboratory paper)	0.1	ton(s)
Waste organic solvents	0.45	ton(s)

# Working with Partners to Build a Better Life

Edge Medical actively fulfils its social responsibilities, continuously deepens industry exchanges and cooperation, works with upstream and downstream partners to build a sustainable supply chain system, and promotes access to advanced medical technologies and treatment solutions for more patients.

Aligned with the United Nations Sustainable Development Goals (SDGs)



# Sustainable Supply Chain

The Company integrates sustainability concepts throughout the supply chain management process. Through institutional standards and process controls, it continuously improves the supply chain's environmental and social responsibility performance and is committed to building a green, responsible and stable supply chain system.

## Supply Chain Management

The Company has formulated a series of institutional documents, including the Supplier Development Management Procedure, Procurement Control Procedure and Market Service Procurement Management Provisions, clearly standardizing requirements for supplier development, admission, evaluation and elimination, and ensuring that suppliers continuously meet quality, delivery and cost requirements.

<b>Supplier categorization and development</b>	Suppliers are categorized according to material type, and their basic information, business strength, technical capability and quality management are investigated and evaluated to ensure they meet the Company's requirements.
<b>Supplier review and admission</b>	After cross-departmental review of the evaluation results, qualified suppliers are included in the List of Qualified Suppliers. Corresponding agreements are signed according to supplier category to clearly define rights and obligations in relation to quality standards, payment terms, acceptance and after-sales service.
<b>Supplier performance evaluation</b>	Suppliers are evaluated annually from four aspects—delivery, quality, price and service—and graded management is implemented based on the scores.
<b>Supplier audit and coaching</b>	For suppliers with relatively low performance evaluation results, annual audit and coaching plans are developed to drive continuous improvement. Where a supplier undergoes a material change, implementation may only proceed after it passes review.
<b>Supplier elimination mechanism</b>	For suppliers that experience major abnormalities, repeated quality issues or fail to cooperate with rectification, the Company initiates elimination procedures and promptly terminates cooperation to ensure supply chain safety and stability.

In addition, the Company classifies and archives relevant data generated during supplier certification and cooperation, establishes supplier files, and ensures that all documents are updated effectively and remain traceable throughout the process.

As of the end of the Reporting Period, the Company had a total of 206 suppliers, of which 143 were located in Guangdong Province, 62 in other regions of China outside Guangdong Province, and 1 overseas supplier (including Hong Kong, Macao and Taiwan). The proportion of suppliers that had signed integrity clauses was 100%.

## Supply Chain Risk Assessment

The Company incorporates sustainability concepts into supply chain risk management and continuously pays attention to suppliers' environmental and social performance in supplier admission and performance evaluation. At the admission stage, the Company focuses on reviewing supplier qualification certificates, production environment and relevant system certifications, and establishes quality assurance and other requirements. At the performance evaluation stage, the Company continuously monitors suppliers' delivery quality, service cooperation and compliance records, and promptly proposes rectification requirements for identified potential risks and follows up on implementation to ensure a stable, safe and controllable supply chain. During the Reporting Period, no product quality incidents caused by supplier-related issues occurred.

## Supply Chain Environmental Management

The Company incorporates environmental performance into its supplier evaluation system and actively encourages suppliers to adopt environmentally friendly products and packaging during cooperation, thereby continuously promoting green procurement. For purchased items subject to cleanliness requirements for the production environment, suppliers are required to provide documentation certifying the cleanliness grade of the production environment to ensure compliance with the Company's environmental management standards. During annual monitoring, the Company focuses on verifying whether delivered products comply with environmental requirements such as RoHS so as to control the use of hazardous substances at the source. At the same time, under equivalent conditions, the Company gives preference to suppliers certified under ISO 14001 environmental management systems, promoting continuous optimization of the supply chain toward greener practices.

# Industry Exchange

At the forefront of industry development, the Company promotes technological innovation and clinical application of surgical robots through international cooperation, hospital-enterprise collaboration and academic co-development, thereby supporting the high-quality development of the industry.

## International Cooperation

In 2025, the Company continued to advance its global presence by entering into strategic partnerships with Dornier MedTech in Europe, Meden-Inmed in Poland, idsMED in Southeast Asia and the AMICO Group in the Middle East, while also promoting the commercial deployment of its products in markets such as Nigeria and Uzbekistan.



1.Strategic cooperation signing ceremony with idsMED under the Fung Group

2.Strategic cooperation with Poland's Meden-Inmed

3.Strategic cooperation with Dornier MedTech

4.Strategic cooperation signed with AMICO Group

5.Successful installation of the multi-port surgical robot in Nigeria

6.The first Chinese surgical robot installed in Uzbekistan

## Hospital-Enterprise Collaboration

The Company continues to deepen the integration of industry, academia and research, joining hands with leading medical institutions to accelerate the deployment of frontier technologies in hospitals at all levels through systematic and platform-based capabilities, allowing remote surgery to evolve from a high-end “demonstration technology” into a “routine capability” that can be promoted and replicated.

## Academic Exchange

The Company actively participated in top domestic and international academic events, showcasing the strength of Chinese intelligent manufacturing on international stages such as Italy and Germany. It also appeared at domestic conferences including the CUDA Annual Meeting, the National Urological Robotic Surgery Conference and the Chinese Medical Doctor Association Congress of Obstetricians and Gynecologists, leading the technological frontier through multi-location interconnected remote surgery demonstrations.



Cooperation agreement signed with Zhujiang Hospital of Southern Medical University



Unveiling ceremony of the Robotic Remote Training Center and Remote Surgery Center at the First Affiliated Hospital, Zhejiang University School of Medicine



15<sup>th</sup> German Robotic Urology Congress




98<sup>th</sup> Congress of the Italian Urological Association



2025 National Urological Robotic Surgery Conference



Launch ceremony of the strategic cooperation project with the Department of Urology of Peking University Third Hospital



Commercial installation completed at Qilu Hospital and rapid clinical breakthrough achieved



2025 Annual Meeting of the Chinese Urological Doctor Association (CUDA)



12<sup>th</sup> Southern Urology Academic Exchange Conference



2025 Chinese Medical Doctor Association Congress of Obstetricians and Gynecologists

# Community Development

Adhering to the mission of “To advance surgical technology, empower surgeons and benefit patients” the Company actively participates in social initiatives and is committed to promoting the extension of quality medical resources to grassroots communities through technological innovation, so that surgical robotics technology can benefit more patients. Such resources were primarily embedded in the Company’s day-to-day operations and support for hospital partnerships, with a focus on enhancing healthcare accessibility, supporting capacity building for medical institutions, and facilitating the extension of quality medical resources to lower-tier markets. During the Reporting Period, the Company had not established any dedicated community donation arrangements, nor had it organized volunteer service activities on a unified basis.

## Fair and Reasonable Pricing

The Company adheres to a responsible pricing philosophy. While pursuing sound operations and continuous innovation, it also takes into account the procurement affordability of medical institutions and the actual payment burden of patients, striving to bring advanced surgical robotics technology into clinical application at more reasonable cost. The Company has established a relatively comprehensive product pricing mechanism, which comprehensively considers factors such as the market competitive landscape, clinical value of products, production costs and patients’ ability to pay, and conducts multidimensional research and cross-validation based on public market information, channel feedback, competitor pricing, hospital procurement conditions and professional consulting data, thereby forming a prudent and standardized basis for price evaluation. Relevant pricing plans are implemented after being reviewed and approved under the management review mechanism, ensuring that product pricing is reasonable, compliant and adaptable to the market. Compared with comparable mainstream international products, the Company adopts more competitive pricing strategies in equipment, consumables and warranty services, which helps reduce the adoption costs of medical institutions and support the optimization of end-user surgical costs, reflecting the Company’s responsible commitment to balancing commercial sustainability with social value creation.

## Enhancing Healthcare Accessibility

The significance of innovation in medical technology lies not only in technological breakthroughs, but also in enabling more medical institutions and patients to truly gain access to and afford high-quality innovative products and services. To this end, the Company actively promotes the adoption and application of surgical robotics in clinical settings. In terms of end-user charges, the fee standards for robot-assisted surgery are mainly subject to caps set by local medical insurance authorities, while hospitals determine pricing based on actual circumstances. On this basis, the Company’s more competitive product pricing is expected to help hospitals reduce overall procurement and usage costs and create room to alleviate patients’ surgical burdens.

At the same time, the Company continues to monitor progress in the inclusion of robot-assisted surgical procedures in medical insurance schemes, supports the gradual inclusion of more procedures with clear clinical value and significant patient benefits within relevant coverage systems, and helps improve the affordability of advanced medical technologies. In addition to the traditional sales model, the Company is also actively exploring diversified cooperation models such as equipment placement, leasing, pay-per-use and procurement of technical services. It also helps medical institutions enhance their technical application capabilities and service coverage by providing training support to partner hospitals, thereby promoting broader and more affordable access to quality medical resources for patients.

## Promoting the Extension of Quality Medical Resources

The Company remains committed to expanding and extending quality medical resources through technological innovation, striving to break the constraints that geography, institutional hierarchy and resource conditions place on high-quality healthcare services, so that surgical robotics technology can benefit a broader patient population.

In China, the Company actively supports the development of regional and grassroots healthcare capacity, helping Qingyuan People’s Hospital achieve the milestone of 100 robotic surgeries and successfully supporting the first gynecologic robotic surgery in northwestern Guangdong in Guangning. This extends quality medical services to the grassroots level and enables more patients to receive precise and minimally invasive surgical treatment close to home. At the same time, leveraging its telesurgery system, the Company has established a cross-regional medical collaboration network and carried out collaborative demonstration projects with The First Affiliated Hospital of Sun Yat-sen University and Qingyuan People’s Hospital. Through intelligent surgical technologies, the Company continues to reshape medical service models and lead the high-quality and normalized development of remote surgery.

Overseas, the Company actively supports the strengthening of global healthcare service capacity through China’s innovative medical equipment, helping to deploy the first Edge Medical robot in a local hospital in Pakistan so that more patients can access advanced robotic surgical treatment without travelling far, demonstrating the inclusive value of Chinese medical technology in improving global health and well-being.



1. The First Affiliated Hospital of Sun Yat-sen University and Qingyuan People’s Hospital Jointly Demonstrate Cross-regional Medical Collaboration, with Edge Medical® Leading the New Normal of Remote Surgery

2. Qingyuan People’s Hospital achieved a major breakthrough of 100 robotic surgeries

3. The first gynecologic robotic surgery in western Guangdong

4. Edge robot supporting charitable healthcare in Pakistan

# Outlook for 2026

Entering 2026, Edge Medical will continue to uphold the principles of “original innovation” and “striving for excellence”, and will continue to drive sustainable development through technological innovation and responsible management.

## In terms of product innovation

the Company will continue to focus on core surgical robotics technologies, further enrich its product portfolio of multi-port, single-port and bronchoscopic surgical robots, and drive products toward greater precision and intelligence. At the same time, it will steadily advance its global expansion so that surgical robotics technology developed in China can benefit more countries and regions.

## In environmental protection

the Company will continue to advance green manufacturing, reduce waste emissions, and promote the application of recyclable materials in equipment manufacturing. At the same time, by using remote surgery technology to reduce patients’ need to travel across regions for treatment, the Company can indirectly reduce carbon footprints and support the sustainable development of the healthcare industry.

## In terms of employee development

the Company will continue to improve its talent development and incentive mechanisms, provide employees with diversified career development paths, and enhance employee satisfaction and sense of belonging by fostering an open, equal and inclusive working environment, thereby building a high-quality and innovative medical technology team.

## In terms of inclusive healthcare

the Company will promote the broad application of remote surgery technology, deepen clinical cooperation with medical institutions at all levels, and facilitate the extension of quality medical resources to the grassroots level. Through continuous technological innovation, it will reduce barriers to application, help narrow the urban-rural healthcare gap and achieve fairer allocation of medical resources.

Looking ahead, Edge Medical will take product innovation as the engine, environmental responsibility as the foundation, employee development as the support, and inclusive healthcare as the objective, and will work hand in hand with global partners to build a responsible and sustainable healthcare ecosystem.

# ESG Index

## Content Index of the Hong Kong Stock Exchange's ESG Reporting Code

Aspect	KPI No.	Description	Section
<b>A1 Emissions</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Emissions
	A1.1	The types of emissions and respective emissions data.	Emissions
	A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Emissions
	A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Emissions
	A1.5	Description of emissions target(s) set and steps taken to achieve them.	Emissions
	A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Emissions
<b>A2 Use of Resources</b>	General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Resource Use
	A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Resource Use
	A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Resource Use
	A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Resource Use
	A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Resource Use
	A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Resource Use
<b>A3 The Environment and Natural Resources</b>	General Disclosure	Policies on minimizing the issuer's significant impacts on the environment and natural resources.	Environmental Management
	A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environmental Management

Aspect	KPI No.	Description	Section
<b>B1 Employment</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Employee Rights and Interests
	B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	Employee Rights and Interests
	B1.2	Employee turnover rate by gender, age group and geographical region.	Employee Rights and Interests
<b>B2 Health and Safety</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Employee Safety
	B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Employee Safety
	B2.2	Lost days due to work injury.	Employee Safety
	B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Employee Safety
<b>B3 Development and Training</b>	General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Employee Development
	B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Employee Development
	B3.2	The average training hours completed per employee by gender and employee category.	Employee Development
<b>B4 Labour Standards</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labor.	Employee Rights and Interests
	B4.1	Description of measures to review employment practices to avoid child and forced labor.	Employee Rights and Interests
	B4.2	Description of steps taken to eliminate such practices when discovered.	Employee Rights and Interests
<b>B5 Supply Chain Management</b>	General Disclosure	Policies on managing environmental and social risks of the supply chain.	Sustainable Supply Chain
	B5.1	Number of suppliers by geographical region.	Sustainable Supply Chain
	B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Sustainable Supply Chain
	B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Sustainable Supply Chain
	B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Sustainable Supply Chain

Aspect	KPI No.	Description	Section
<b>B6 Product Responsibility</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Quality Management
	B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Quality Management
	B6.2	Number of products and service related complaints received and how they are dealt with.	Quality Management
	B6.3	Description of practices relating to observing and protecting intellectual property rights.	Intellectual Property Protection
	B6.4	Description of quality assurance process and recall procedures.	Quality Management
	B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	Customer Service
<b>B7 Anti-corruption</b>	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Business Ethics
	B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Business Ethics
	B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	Business Ethics
	B7.3	Description of anti-corruption training provided to directors and staff.	Business Ethics
<b>B8 Community Investment</b>	General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Community Development
	B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, sport).	Community Development
	B8.2	Resources contributed (e.g. money or time) to the focus area.	Community Development
<b>D Climate-related Disclosures</b>	Governance	Governance	Climate Change
	Strategy	Climate-related risks and opportunities	Climate Change
		Business model and value chain	Climate Change
		Strategy and decision-making	Climate Change

Aspect	KPI No.	Description	Section
<b>D Climate-related Disclosures</b>	Strategy	Financial position, financial performance and cash flows	Capabilities Relief. The Company currently does not have the capability to track and record the relevant financial data in a manner that would enable separate, accurate and complete disclosure.
		Climate resilience	Capabilities Relief. The Company has not yet conducted climate-related scenario analysis and, accordingly, did not make specific disclosure on climate resilience for the Reporting Period. Going forward, the Company will progressively enhance the relevant work, taking into account regulatory requirements and actual circumstances.
	Risk management	Risk management	Climate Change
		GHG emissions	Climate Change
		Climate-related transition risk	Climate Change
		Climate-related physical risk	Climate Change
		Climate-related opportunities	Climate Change
	Metrics and target	Capital deployment	Capabilities Relief. As the Company has not yet established clear classification definitions, data collection procedures and accounting standards for the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities, the relevant information is not currently available for separate, accurate and complete disclosure. Accordingly, such information was not disclosed in this Report.
		Internal carbon prices	The Company does not apply a carbon price in decision-making during the Reporting Period.
		Remuneration	Climate-related considerations have not been factored into the Company's remuneration policy during the Reporting Period.
		Industry-based metrics	Not yet applied.
		Climate-related targets	Climate Change
		Applicability of cross-industry metrics and industry-based metrics	Climate Change

# Feedback Form

Dear Reader,

Hello! Thank you for taking the time to read the 2025 Environmental, Social and Governance (ESG) Report of Shenzhen Edge Medical Co., Ltd. To better understand your expectations and demands regarding our work, we sincerely invite you to participate in this survey and share your views and suggestions on our ESG report and related work. Every suggestion you provide is valuable to us. We look forward to your feedback.

Your overall impression of this report:

Excellent     Good     Fair     Poor     Very Poor

How do you rate the quality of information disclosed in this report?

Excellent     Good     Fair     Poor     Very Poor

1.How do you evaluate the structure of this report?

Excellent     Good     Fair     Poor     Very Poor

2.How do you evaluate the reading experience of this report?

Excellent     Good     Fair     Poor     Very Poor

3.In your opinion, what deficiencies does this report have?

---

4.What information would you like us to disclose on a regular basis?

---

5.What suggestions do you have for Edge Medical's ESG work?

---

You may contact us through the following channels:

Tel: 400-860-9000

Email: [contact@edgemed.cn](mailto:contact@edgemed.cn)

Mailing Address: Room 1901, Building 2B, Smart Park Phase II, Baolong Street, Longgang District, Shenzhen, PRC